Real-World Switch Rates for Patients With Psoriasis Initiating Risankizumab Stratified by Body Mass Index

Jashin J. Wu,[1] Manish Patel,[2] Huzefa Photowala,[2] Chao Li,[2] April W. Armstrong[3]

[1]Department of Dermatology, University of Miami Miller School of Medicine, FL, USA;
[2]AbbVie Inc., North Chicago, IL, USA; [3]UCLA, Los Angeles, CA, USA

OBJECTIVE

To quantify real-world switch rates for patients with psoriasis treated with risankizumab, stratified by body mass index categories and weight quartiles

CONCLUSION

In this real-world study, treatment patterns through 12 months among patients initiating risankizumab for psoriasis were consistent regardless of BMI or body weight quartile

References
1. Armstrong AW, et al. *JAMA Dermatol.* 2021 Aug 1; 157(8):940-6.
2. Budu-Aggrey A, et al. *PLoS Med.* 2019;16(1):e1002739.
3. Yeung H, et al. *JAMA Dermatol.* 2013;149(10):1173-9.
4. Abramczyk R, et al. *Diabetes Metab Syndr Obes.* 2020;13:3571-7.
5. Kerdel F and Zaiac M. *Dermatol Ther.* 2015;28(6):390-403.
6. Merola JF, et al. *Dermatol Ther (Heidelb).* 2022;12(10):2201-16.
7. Foley P, et al. Poster P9780 presented at: Annual Meeting of the American Academy of Dermatology (AAD); March 1–5, 2019, Washington, DC.

INTRODUCTION

- Psoriasis (PsO) is a chronic, inflammatory skin disorder that affects approximately 3% of adults in the US[1]
- While PsO typically affects the skin, it is also associated with other systemic comorbidities such as psoriatic arthritis, cardiometabolic disease, diabetes, and obesity[2–4]
- Switching therapies is common in patients with PsO due to poor treatment outcomes, such as lack of efficacy or safety/tolerability issues, which are notably more pronounced in patients who are refractory to treatment[5]
- Studies have also linked metabolic syndrome and its components, especially obesity, to decreased biologic treatment efficacy in patients with PsO[6]
- In a long-term clinical setting, risankizumab efficacy was consistent independent of weight/body mass index (BMI) status

METHODS

Database

- The Optum® Market Clarity Data, a database which includes insurance claims linked with electronic medical records data, was used to identify patients who initiated risankizumab between May 1, 2019 and September 30, 2022

Eligibility Criteria

- Adults initiating risankizumab
- ≥1 psoriasis diagnosis (ICD codes) on or prior to biologic initiation
- ≥6 months of continuous insurance benefits pre- and 12 months post-biologic initiation
- No other biologics or apremilast in baseline period (targeted immuno modulator-naïve patients)
- Patients with weight/height data available on or in the 12 months prior to start of risankizumab

Study Outcome

- Switch rate at 12 months:
  − The proportion of patients who switched to a different biologic or apremilast in the 12 months follow-up period
  − Switch rates over 12 months were evaluated among all risankizumab initiators and stratified by:
    ○ BMI category (BMI <25 Kg/m^2, 25 to <30 Kg/m^2, ≥30 Kg/m^2)
    ○ Weight quartiles of the population (≤73.94 Kg, >73.94 to ≤89.40 Kg, >89.4 to ≤105.2 Kg, >105.2 Kg)

Statistical Analysis

- Fisher's exact test was conducted to compare switch rates across different BMI categories and weight quartiles

RESULTS

Baseline Demographics

- A total of 367 patients were included in this analysis; the mean (SD) age of patients was 47.7 (14.3) years, 52.9% were female, 5.5% were Black, and 83.1% were White
- Among patients initiating risankizumab, 19.4% had a BMI of <25 Kg/m^2, 30.2% had a BMI of 25 to <30 Kg/m^2, and 50.4% had a BMI ≥30 Kg/m^2
- Each body weight stratified subgroup contained approximately 25% of the patient population

Switch Rates

- The switch rate by 12 months for all patients initiating risankizumab was 3.8%
  − There were no significant differences in switch rates between BMI categories (P = .589)
 − There were no significant differences in switch rates between body weight quartiles (P = .299)

Baseline Demographics for Patients That Initiated Risankizumab

	All patients (N = 367)
Age, mean (SD), years	48 (14.3)
Sex	
Female	194 (52.9)
Male	173 (47.1)
Race	
Black	20 (5.5)
Asian	13 (3.5)
White	305 (83.1)
Other/unknown	29 (7.9)
Region	
Midwest	164 (44.7)
Northeast	60 (16.4)
Other/unknown	14 (3.8)
South	98 (26.7)
West	31 (8.5)
Insurance type	
Commercial	334 (91.0)
Medicaid	13 (3.5)
Medicare	19 (5.2)
Unknown	1 (0.3)

All data are n (%) unless stated otherwise.

RESULTS CONTINUED

Real-World Biologic Switch Rates Among Risankizumab Initiators Over 12 Months by BMI Category

- All (N = 367): Non-Switcher 96.2%, Switcher 3.8%
- <25 kg/m^2 (n = 71): Non-Switcher 94.4%, Switcher 5.6%
- 25 to <30 kg/m^2 (n = 111): Non-Switcher 97.3%, Switcher 2.7%
- ≥30 kg/m^2 (n = 185): Non-Switcher 96.2%, Switcher 3.8%

BMI, body mass index.

Real-World Biologic Switch Rates Among Risankizumab Initiators Over 12 Months by Body Weight Quartile

- All (N = 367): Non-Switcher 96.3%, Switcher 3.8%
- 1st (≤73.94 kg) (n = 94): Non-Switcher 93.6%, Switcher 6.4%
- 2nd (>73.94 to ≤89.40 kg) (n = 93): Non-Switcher 98.9%, Switcher 1.1%
- 3rd (>89.4 to ≤105.2 kg) (n = 93): Non-Switcher 96.8%, Switcher 3.2%
- 4th (>105.2 kg) (n = 93): Non-Switcher 95.7%, Switcher 4.3%